ALL Hub

⭐ALL Hub spotlight | ECOG-ACRIN E1910: A phase III trial⭐ The ECOG ACRIN-led E1910 trial is investigating the efficacy and safety of blinatumomab + chemotherapy vs chemotherapy alone in patients with newly diagnosed BCR::ABL1-negative B-ALL; see the latest results here.

🚨 News 🚨 Obecabtagene autoleucel has been granted marketing authorization by the @EU_Commission for the treatment of patients aged ≥26 years with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Read more: loom.ly/ZDQxgwk #ALLsm #leusm #MedNews #MedEd

Did you know you can filter content on the ALL Hub website depending on your specific interests – whether that is by ALL type, therapeutics, trials, or congresses? 👉 loom.ly/_nYocRg #allsm #leusm #MedEd

📝 Preliminary results from the phase I/II SYRUS trial, presented by Ibrahim Aldoss at #EHA2025, found that surovatamig (AZD0486) achieved an ORR of 83% at a target dose of 15 mg in patients with R/R B-ALL. More news: lymphoblastic-hub.com #ALLsm #leusm #MedicalCongress…

🚨 News 🚨 @EU_Commission has granted marketing authorization to obecabtagene autoleucel for the treatment of patients aged ≥26 years with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Read more: loom.ly/ZDQxgwk #ALLsm #leusm #MedNews #MedEd

📝 Follow-up results from ZUMA-3 presented at #EHA2025 demonstrate a 5-year OS rate of 40% with a median OS of 25.6 months with brexu-cel for adult patients with R/R B-ALL. More news: lymphoblastic-hub.com/trials/zuma-3 #ALLsm #leusm #MedNews #MedEd

New data 📝 5-year follow-up results from ZUMA-3 presented at #EHA2025 show brexu-cel continues to provide durable benefit for adults with R/R B-ALL regardless of age, prior therapy, or subsequent allo-HSCT status. Learn more: loom.ly/28wLEuA #ALLsm #leusm #MedNews…

📝 A subgroup analysis from the ECOG-ACRIN E1910 trial presented at #EHA2025 supports the use of Blina + chemo consolidation in patients aged <55 y with MRD-negative BCR::ABL1-negative BCP-ALL. More news: lymphoblastic-hub.com/trials/ecog-ac… #ALLsm #leusm #MedNews #MedEd

New data 📝 Subgroup analysis from ECOG-ACRIN E1910 presented at #EHA2025 shows higher 3-year OS and RFS with Blina + chemo (92% & 86%) vs chemo (67% & 66%) in patients <55 y with MRD-negative BCR::ABL1-negative B-ALL. Learn more: loom.ly/8al1z0M #ALLsm #leusm #MedNews…

📝 Long-term follow-up data from the CALGB 10403 study presented by Wendy Stock at #EHA2025 found that MRD negative vs positive status was associated with longer OS in AYA patients with ALL (p = 0.0037). More news: lymphoblastic-hub.com #ALLsm #leusm #MedicalCongress #MedEd

New data 📝 Long-term follow-up data from the CALGB 10403 study presented by Wendy Stock at #EHA2025 show a median survival of 142 months, with 56% of AYA patients with ALL achieving 10-year survival. Learn more: loom.ly/y_r8z2I #ALLsm #leusm #MedicalCongress #MedEd

Catch up on the latest developments in #ALL from #EHA2025 with live social media coverage from the ALL Hub (Part 4). Read more here: loom.ly/rRwmwEw #ALLsm #leusm #MedicalCongress

Thank you to our funders, who make it possible for us to deliver the ALL Hub. • Amgen • Autolus • Jazz • Pfizer • The Hipocrate Conference Institute, an association of the Servier Group. #allsm #leusm

Catch up on the latest developments in #ALL from #EHA2025 with live social media coverage from the ALL Hub (Part 3). Read more here: loom.ly/FLu-2WQ #ALLsm #leusm #MedicalCongress

🚨 News 🚨 The @US_FDA has reduced barriers to accessing CAR T-cell therapies by removing REMS requirements, shortening monitoring periods, and reducing driving restrictions. CAR-T uptake is expected to double. Read more: loom.ly/6YBr8gM #ALLsm #leusm #MedNews

🎥 At our latest Steering Committee Meeting, @Gilles_Salles, @MSKCancerCenter, chaired a discussion on CELMoDs for the treatment of non-Hodgkin lymphoma. Check out the full video here! loom.ly/s3O4Vyk #lymsm #Lymphoma

⭐ALL Hub spotlight | The ECOG ACRIN-led E1910 trial of blinatumomab plus chemotherapy vs chemotherapy alone in patients with newly diagnosed BCR::ABL1-negative B-ALL⭐ Discover the latest clinical data here: loom.ly/qf8jEeQ #ALLsm #leusm #MedicalEducation

Catch up on the latest developments in #ALL from #EHA2025 with live social media coverage from the ALL Hub (Part 2). Read more here: loom.ly/sSF9Mr4 #ALLsm #leusm #MedicalCongress

🚨 News 🚨 The CHMP of the @EMA_News has recommended granting conditional marketing authorization to a novel, cryopreserved HSCT product containing dorocubicel and unexpanded CD34- cells, each derived from the same cord blood unit, for the treatment of adults with hematologic…

Catch up on the latest developments in #ALL from #EHA2025 with live social media coverage from the ALL Hub (Part 1). Read more here: loom.ly/TNNwkmg #ALLsm #leusm #MedicalCongress